PYXS
Pyxis Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$92.36M
P/E Ratio
—
EPS
$-1.28
Beta
1.42
52W High
$5.55
52W Low
$0.87
50-Day MA
$1.47
200-Day MA
$2.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $13.86M |
| Gross Profit (TTM) | $11.47M |
| EBITDA | $-77.33M |
| Operating Margin | -159.50% |
| Return on Equity | -91.40% |
| Return on Assets | -41.10% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $0.85 |
| Price-to-Book | 1.75 |
| Price-to-Sales (TTM) | 6.66 |
| EV/Revenue | 3.279 |
| EV/EBITDA | 1.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $62.83M |
| Float | $40.40M |
| % Insiders | 22.46% |
| % Institutions | 37.64% |
Analyst Ratings
Consensus ($6.88 target)
1
Strong Buy7
Buy1
HoldData last updated: 4/9/2026